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Pain is a common symptom in older people. It is possible that pain is underreported
in older persons due to an incorrect belief that it is an inevitable part of aging. Opioid
analgesics are potent medications, with confirmed efficacy for the treatment of moderate
to severe pain. These drugs are commonly used in older persons. However, there is
insufficient evidence regarding safety of opioids in older patients. One of the reasons
for this is the lack of randomized, controlled clinical trials. People of advanced age
often have comorbidites and use other prescription drugs, as well as over-the-counter
(OTC) compounds, thus making them more suceptible to the risk of interactions with
opioids. Significant pharmacokinetic and pharmacodynamic changes that occur with
advancing age increase the risk of adverse effects of opioids. There are also some
discrepancies between guidelines, which recommend the use of lower doses of opioids
in older patients, and the findings in the literature which suggest that pain is often
undertreated in this age group. It seems that there are significant variations in the
tolerability of different opioid analgesics in older people. Morphine, fentanyl, oxycodone,
and buprenorphine are still the preferred evidence-based choices for add-on opioid
therapy for these patients. However, the safety and efficacy of other opioids in older
patients, especially if comorbidities and polypharmacy are present, is still questionable.
This review addresses the most important aspects of the use of opioids in older persons,
focusing on pharmacokinetics, pharmacodynamics, adverse effects, and interactions.
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BACKGROUND
The population of older people is normally classified as being aged 65 years and above. The
projections of the Administration of Aging are that by 2030 the population of people over the age
of 65 will increase two-fold in the United States (Atkinson et al., 2013). The proportion of people
aged 60 and over is also rising every year throughout Europe, including our country (Pergolizzi
et al., 2008).
Pain is common in the older population. It is important to assess the pain, treat, and
evaluate it. Also, it is important to recognize and address the side effects of analgesic drugs that
can be very challenging due to the alterations in the pharmacokinetics of medications which
Prostran et al. Opioids in Older Age
occur with normal physiologic aging (Chau et al., 2008). The
use of opioid analgesics in the treatment of moderate to severe
pain in people of advanced age is additionally complicated by the
presence of other diseases (comorbidities) and the use of other
medications which increases the risk of possible interactions.
Pain may be underreported by older persons due to the
incorrect belief that it is necessarily associated with aging. In
patients with cancer pain, it is underreported because of the fear
of disease progression. Therefore, the caregivers and relatives are
sometimes a more reliable source of information (Ferrell et al.,
1991).
The studies on the treatment of pain in older patients are
sparse. Mercadante and Giarratano in their systematic review
of differences between adults and older persons and between
male and female patients in randomized clinical trials on pain
identified only three studies that focused on the population of
advanced age (Mercadante and Giarratano, 2014).
There is an increasing number of articles focused on pain
assessment in patients with dementia (Warden et al., 2003).
Managing pain in patients with dementia is a challenge. Dublin
et al. (2015) in a prospective cohort study examined whether
prescribing of opioid medications is associated with a higher risk
of dementia or with greater cognitive decline. They concluded
that people with the heaviest opioid or non-steroidal anti-
inflammatory drugs (NSAIDs) use had slightly higher dementia
risk than people with little or no use.
Older patients with dementia or during terminal phases
of diseases are treated as vulnerable subjects. It is a special
problem to conduct clinical trials with vulnerable subjects due
to their (in)ability to understand and sign the informed consent.
Informed consent is a process of communication between a
patient and physician that results in the patient’s permission or
agreement to undergo a specific medical procedure (Prostran
et al., 2012). It may be one of the reasons why so few randomized,
controlled clinical trials on the use of opioids in older people are
available.
OPIOID ANALGESICS IN OLDER PERSONS
Chronic pain occurs in 45–85% of the older population
and the need to treat chronic pain is growing substantially.
Unfortunately, the treatment of chronic pain is not always
correctly targeted, which leads to a reduced quality of life, with
decreased socialization, depression, sleep disturbances, cognitive
impairment, disability, and malnutrition (Gianni et al., 2009).
Opioids are drugs for the treatment of acute and chronic,
moderate to severe pain, such as nociceptive and neuropathic
pain. These drugs belong to a class of drugs with a known efficacy
in pain, in both young and older patients (Kahan et al., 2006;
Kuehn, 2009).
Up to 76% of older people in the community experience pain
(Abdulla et al., 2013). There are no gender differences among 65
to 80-year-olds in terms of global pain status (LeResche et al.,
2015).
The American Geriatric Society suggests the use of opioids
in older persons (American Geriatric Society Panel, 2009). It
is recommended to start with paracetamol and add on opioids
when needed to manage pain in a stepwise approach (Veal
and Peterson, 2015). The decision as to which opioid should
be added on to paracetamol is a difficult one due to a lack of
evidence regarding safety and tolerability. Most of the clinical
trials exclude the frail patients and/or minimally include older
people. A retrospective analysis of a consecutive sample of
patients with cancer admitted to a home care program was
performed and it was shown that in the older population there
was a lower consumption of opioids, the subcutaneous route for
administration was used more frequently, and palliative sedatives
were required less often (Mercadante et al., 2016).
World Health Organization recommends that the treatment
of pain in Step 3 includes opioids such as morphine,
hydromorphone, fentanyl, levorphanol, methadone, and
oxycodone. For the effective and safe use of these drugs it is
well to be familiar with opioid pharmacokinetics, equi-analgesic
dosing, and adverse effects. Antiepileptic drugs, antidepressants,
and local anesthetics as adjuvant analgesics have a role in
the treatment of neuropathic pain. Adjuvant analgesics can
enhance the effects of opioids, especially in cases where opioid
responsiveness may be in question (Prommer and Ficek, 2012).
Patients with moderate to severe pain, pain related to
functional organ impairment, or diminished pain-related quality
of life should be considered for opioid therapy (low quality
of evidence, strong recommendation; Kaye et al., 2010). Also,
patients taking opioid analgesics should be reassessed often for
attainment of treatment goals, adverse effects, and safe and
responsible medication use (moderate quality of evidence, strong
recommendation).
Previous studies have shown that older patients require lower
doses of opioids. Studies comparing the efficacy and tolerability
of opioids, such as fentanyl patches (Menten et al., 2002),
morphine (Kaiko, 1980), and sublingual buprenorphine (Nasar
et al., 1986) in the older population and other populations have
shown that the older people respond, as well as, or even better, to
opioid treatment than younger age groups. Additionally, patients
who underwent hip or knee arthroplasty under general anesthesia
were identified in a retrospective cohort study design; older
patients received lower doses of opioids intraoperatively andwere
less likely to require rescue analgesia (Ladha et al., 2015). Despite
responding well to lower doses of analgesics, it has been shown
that a significant proportion of older persons, either at nursing
homes or community-living, have inadequately addressed daily
pain associated with cancer or other conditions (Bernabei et al.,
1998; Landi et al., 2001).
THE EFFICACY OF DIFFERENT OPIOIDS IN
THE TREATMENT OF PAIN IN OLDER
PERSONS
Morphine has been used to treat malignant pain for many years
and has been the subject of a large number of trials, generally
involving small numbers of patients. Also, morphine has been
used for the management of the persistent non-malignant pain
too, often as a comparator to newer opioids where similar
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efficacy has been demonstrated (Lee et al., 2015). Morphine
is metabolized in the liver. Morphine-6-glucuronide (M6G) is
potent analgesic and morphine-3-glucuronide (M3G) may cause
neuroexcitatory effects. Thesemetabolites are excreted in bile and
then feces and urine after the last dose is given. Accumulation of
the metabolites in patients with renal impairment, may cause side
effects requiring dose adjustment, or switching to an alternative
opioid (Gianni et al., 2009).
Recently, in one study it was observed that liquid morphine
reduced the chronic non-cancer pain in 10 older patients (with
a mean age of 75.5 years and medical co-morbidities; Lee
et al., 2015). Future larger and well-designed studies should
focus on the use of liquid morphine for older people. OROS
hydromorphone (Jurnista) is a once-daily, extended-release
formulation that uses the OROS push-pull technology to provide
controlled release of the semi-synthetic opioid hydromorphone
(Lussier et al., 2010). According to Lussier et al. (2010), once daily
usage has an advantage over longer-acting formulations which
are used twice-daily (Lussier et al., 2010).
A combination of morphine and gabapentin produces better
analgesia than the individual drugs or placebo (Mao et al., 2011).
Similar efficacy to newer opioids, such as oxycodone, fentanyl,
and methadone has been demonstrated (van Ojik et al., 2012).
Oxycodone is used in different types of surgical procedures
and patient groups, from preterm newborns to older patients
(Kokki et al., 2012). Variability of different enteral drug
formulations will decrease the need for intravenous patient-
controlled analgesia but it will increase the use of transmucosal
administration and enteral oxycodone-naloxone controlled-
release tablets.
Fentanyl, as a short-acting synthetic pure opioid, offers an
excellent option for the treatment of cancer and chronic pain
(Panagiotou and Mystakidou, 2010). Intranasal fentanyl has
been investigated to assess its potential as a well-tolerated acute
postoperative breakthrough pain relief medication. It has been
shown to be superior to oral transmucosal fentanyl for the
treatment of cancer breakthrough pain. It had been reported
for postoperative or acute pain treatment of children and adults
in the pre-hospital and hospital settings, but it had not been
investigated in people of advanced age.
Recent study by Likar et al. (2008) in patients with moderate
and severe pain showed that transdermal buprenorphine
benefited patients to a comparable or even higher extent in 65-
year-olds compared with the younger age group, supporting
the need to address the problems with underprescribing
in this age group (Likar et al., 2008). In one prospective,
observational, multicenter study of patients with various chronic
pain conditions the safety, perceptions, and discontinuation
of treatment with transdermal buprenorphine patches were
assessed. In patients with arthritis or other musculoskeletal
disorders this patches were “effective” or “very effective” at
relieving pain and they were “satisfied” or “very satisfied” with
this therapy (Serpell et al., 2015).
Tapentadol as a newer opioid, acts on both the mu receptors
and on neuronal reuptake of noradrenaline. This drug has no
significant analgesically active metabolites, which have some
advantages, particularly in comparison with tramadol (Veal and
Peterson, 2015). Tapentadol is a weak opioid and the conducted
trials were often methodologically poor. There is no sufficient
data to support the use of newer drug tapentadol over other
opioids. Other opioids have been longer on the market and are
less expensive.
Dextropropoxyphene has a long half-life in older people
and has been associated with a significant risk of side
effects (Becquemont et al., 2014). It was observed that
dextropropoxyphene market withdrawal had no consequences
on the intensity or impact of chronic pain in older patients.
Pethidine has an active metabolite that accumulates in older
people with kidney failure (Wilder-Smith, 2005).
There is insufficient data on the use of methadone as an
analgesic in the older population with cancer. Because of its
pharmacological characteristics it must be used by trained
personnel. Several recommendations are proposed for its use as
an analgesic in the treatment of cancer pain in the older age
(Taberna et al., 2014).
Morphine, fentanyl, oxycodone, or buprenorphine are still the
preferred evidence-based choices for add-on opioid therapy for
older people or frail patients (Veal and Peterson, 2015).
PHARMACOKINETICS OF OPIOIDS
Aging can bring some changes in the pharmacokinetics of
drugs. Prescribing pain medications within the older population
requires the skill of a very knowledgeable physician to navigate
through the numerous variables (e.g., physiologic changes,
comorbid conditions, multiple medications) that make the older
patients a heterogeneous and complex population to treat
(Pergolizzi et al., 2008; Vezmar Kovacˇevic´ et al., 2014). The
pathophysiologic profile of older adults significantly changes
with age. Decline in organ function, particularly the renal and
hepatic functions, which are critical in the clearance of ingested
substances, dictates the pharmacokinetic properties of many
drugs (Tumer et al., 1992).
Absorption can be altered because of decreased
gastrointestinal blood flow and increase of gastric pH. With
aging, there are changes in body composition: increase in adipose
tissue, decrease in body mass, and decrease in body water, what
can have influence on the distribution of drug (Chau et al., 2008).
Also, decreasing hepatic blood flow can decrease metabolism
of drugs. The first pass of metabolism opiates can be reduced
in older age (Tegeder et al., 1999). Also, decreased glomerular
filtration rate can lead to accumulation of metabolites of opioids
and to more adverse effects.
Protein binding could represent an important site of
interaction (Table 1). Most of the drugs bind to albumin, but
buprenorphine binds to alpha and beta globulins. As a result,
drug–drug interactions related to protein binding for this drug
is small (Pergolizzi et al., 2008).
Most of opioids are metabolized by CYP P450 isoenzymes
with a variability that is largely determined by genetic
polymorphisms (Gianni et al., 2009; Table 1). CYP
polymorphisms may account for high rates of side-effects
or diminished efficacy in affected patients. Oxycodone
and tramadol, are metabolized mostly by CYP 2D6, and
buprenorphine is metabolized by CYP 3A4. CYP is among the
principal pathways of drug metabolism for several drugs, and
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TABLE 1 | Pharmacokinetics of selected opioids.
Opioid Plasma protein Volume of Half-life Phase I Phase II Major
binding (%) distribution (l/kg) (t1/2) metabolism metabolism metabolites
Morphine 30 245 3 CYP3A UGT2B7 Morphine-3-glucuronide (M3G)—neuroexcitatory
effects
Morphine-6-glucuronide (M6G)—
analgesic effect
Hydromorphone 20 91.5 2.6 UGT2B7 Hydromorphone-3-glucuronide
UGT1A3
Fentanyl 84 4 3.5 CYP3A Norfentanyl-inactive
Tramadol 20 2.6 6.7 CYP3A Nortramadole-inactive
CYP2D6 O-desmethyltramadol-active
Oxycodone 45 2.6 3.7 CYP3A UGT2B7 Oxymorphone
CYP2D6 Noroxycodone
Methadone 85–90 1–8 8–59 CYP3A No active metabolites
Codeine 7–25 3–6 3–4 CYP3A UGT2B7 Codeine-6-glucuronide (C6G)
CYP2D6 Morphine
Norcodeine
Tapentadol 20 540 4 CYP2D6 UGT1A9 No active metabolites
CYP2C9 UGT2B7
CYP2C19
Pethidine 40 3–5 4 CYP2D6 Norpethidine (neurotoxic,
analgesic effect)
CYP3A
CYP2C19
Dextropropoxyphene 70–80 16 15 CYP3A Nordextropropoxyphene
Buprenorphine 96 188–335 3–4 CYP3A4
CYP2C8
UGT1A1
UGT1A3
UGT2B7
Norbuprenorphine
Buprenorphine-3-glucuronide
Norbuprenorphine-3-glucuronide
this could represent a relevant problem in older patients treated
with complex polypharmacological regimens (Pergolizzi et al.,
2008). A reduction of ∼20% in the metabolism of CYP 2D6
substrates was observed in older population (Dorne et al., 2002;
O’Connell et al., 2006), whereas such a finding has not been
confirmed for the CYP 3A subfamily. Certain pharmacokinetics
parameters of some opioids are shown in Table 1.
ADVERSE EFFECTS OF OPIOIDS
Adverse effects of opioids are well-known: nausea,
constipation, urinary retention, pruritus, respiratory depression,
cardiovascular, and central nervous system side effects (Vucˇkovic´
et al., 2004). The analysis of the impact of opioid treatment on
terminal cancer patients on consciousness, appetite and thirst
was performed in one randomized controlled trial. Morphine,
fentanyl, oxycodone or codeine were used for palliative treatment
in these patients. Adverse event incidence rates were 25% for
constipation, 23% for somnolence, 21% for nausea, 17% for
dry mouth, and 13% for vomiting, anorexia, and dizziness.
Adverse effects as asthenia, diarrhea, insomnia, mood change,
hallucinations, and dehydration occurred at incidence rates of
5% and below (Wiffen et al., 2014).
The principle “start low, go slow” is highly recommended
when treatment with opioids is initiated. Profile of the adverse
effect of opiates is similar for all age groups, although older
patients are at greater risk due to comorbidities and interactions
with other medications (Chau et al., 2008). German guideline
for long-term use of opioids recommends a critical check after
3 months in non-cancer pain and in case of dosing over
120mg morphine equivalents is advisable, especially for older
persons. Cognitive effects and sedation occur frequently in
chronic non-malignant pain populations receiving long-term
opioid therapy and are among the most common reasons
patients discontinue opioid use (Dhingra et al., 2015). Suggested
recommendation from The European Association of Palliative
Care (EAPC) Research Network for management of opioid
side effects include the following: dose reduction, symptomatic
management of the adverse effects using drugs targeting
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the symptoms, opioid rotation, and switching the route of
administration (Chau et al., 2008). The risk of falls and fractures,
which is a special concern in older patients may be reduced
TABLE 2 | Serious opioid interaction outcomes.
Opioids
+
Alcohol Sedatives Antihistamines Antipsychotics Muscle relaxants
Additive/synergistic interaction
Respiratory depression
Hypotension
Sedation
Coma
Death
by using longer acting opioids instead of short acting opioids
(Schuler and Grießinger, 2015).
The difference between younger and older population who
used fentanyl-based intravenous patient-controlled analgesia
(IV-PCA) after surgery was evaluated in one retrospective
analysis of 10,575 patients. It was concluded that a larger
proportion of older patients required rescue antiemetics despite
lower incidence of postoperative nausea and vomiting compared
to the younger (Koh et al., 2015). Also, there was a single
report of opioid (fentanyl)-induced muscle rigidity causing life-
threatening respiratory compromise in a 79 old male patient
(Dimitriou et al., 2014).
A further study focused on various opioids and their
therapeutic benefits and risks in older persons, particularly
levorphanol, tapentadol, and transdermal buprenorphine.
Levorphanol was found to be similar to methadone regarding
efficacy, but without pharmacokinetic and other interactions
of methadone. Tapentadol was associated with significantly
less gastrointestinal distress and constipation. Transdermal
buprenorphine had less risk for the toxicities associated with
conventional opioids and with compliance benefits (Atkinson
et al., 2013).
INTERACTIONS OF OPIOIDS
Drug interactions are common with opioids and represent an
important safety issue. Clinical studies indicate that 80% of
TABLE 3 | Interactions of opioids with other drugs.
Stimulants CNS Increase of ventricular arrhythmias (methadone+atomoxetine)
Antiepileptic drugs Dextropropoxyphene increases the effect of carbamazepine
Tricyclic antidepressants Increase of sedative effects of opioids
Increase of toxic effects (convulsions, e.g., tramadol)
Inhibition of morphine glucuronidation
Monoamine oxidase inhibitors (MAOIs) Excitation and depression of CNS (pethidine, tramadol)
Selective serotonin reuptake inhibitors (SSRIs) Toxic CNS effects (convulsions, tramadol)
Anticoagulants Increase of anticoagulant effects (dextropropoxyphene, tramadol)
Antiarrhythmics Merphine can increase the concentration of esmolol in plasma
Drugs affecting gastrointestinal tract Metoclopramide and domperidone antagonize the gastrointestinal effects of opioid analgesics
Cimetidine inhibits the metabolism of opioids
Ranitidine decreases the concentration of morphine and conversion to active metabolites
Antibacterial drugs Opioids decrease the concentration of ciprofloxacin
Erythromycin increases opioid concentration
Rifampicin decreases opioid concentration
Antiviral drugs Metadone can increase the concentration of zidovudine
Ritonavir can increase the concentration of opioid analgesics (fentanyl, petidine, dextropropoxyphene)
Antifungal drugs Vorikonazol increases concentration of methadone and alfentanyl
Ketoconazole increases the concentration of opioid analgesics
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patients over the age of 65 years have at least one chronic
condition while 50% have more than one. The same age group
uses between 2 to 6 prescribed medications and 1 to 3.4
non-prescription medications daily (Stewart and Cooper, 1994;
Larsen and Martin, 1999). The risk of adverse drug reactions
increases with the number of medications used (Larsen and
Martin, 1999). Older people may be particularly susceptible
to unintentional misuse of prescription opioids because high
rates of polypharmacy and a high prevalence of chronic pain.
Results of one study showed that population rates of misuse of
prescription opioids were higher in older than in younger adults
and those rates among the older ages increased each year. Also,
it was reported that serious medical outcomes among the older
population followed an increasing linear trend (West and Dart,
2016; some serious opioid outcomes are shown in Table 2).
A general list of medications that many older patients are
commonly prescribed include cardiovascular drugs (thiazide
diuretics, beta-blockers, angiotensin-converting enzyme
inhibitors); antidiabetic drugs (metformin, sulfonylureas,
thiazolidinediones); bronchodilators, and steroid inhalers such
as fluticasone/salmeterol, tiotropium, albuterol; non-sedating
antihistamines, and steroid, nasal sprays (Maggiore et al.,
2010). The most common interactions of opioids with other
medications are shown in Table 3.
CONCLUSION
The pharmacologically-guided approach to the treatment of
moderate to severe pain in older persons requires a systematic
understanding of the pharmacokinetics and pharmacodynamics
of analgesics. An understanding of the changes associated with
aging is very important for clinical use of opioids. The absence of
randomized controlled trials in the older population emphasizes
the importance of relying on clinical judgment. While a number
of opioids may be commonly used in older people, some
representatives of this class have an unacceptable risk to frail
older patients. It is important to follow guidelines for use of
opioids in older age.
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